AmorChem spins out Mperia, invests $1 mln in Series A round

AmorChem has spun out Montréal-based biotechnology startup Mperia Therapeutics Inc and invested $1 million in the latter's Series A financing. As part of the deal, AmorChem transferred to the company all rights to a novel immunotherapy based on CD36 technology, which addresses diseases involving chronic inflammation, such as age-related macular degeneration. Maxime Ranger was appointed Mperia's president and CEO, and the Université de Montréal's Dr. Huy Ong, its chief scientific officer. AmorChem is the seed-stage fund of Canadian life sciences venture capital firm GeneChem.

CanadaNorth AmericaBriefs